Chronic obstructive pulmonary disease is one of the world’s leading causes of death - more than 300 million live with the ...

Although these products might confer significant advantages over the currently available treatments, there is still a huge unmet need for drugs that prevent the progression of COPD. Companies are ...

Joining us is the company Sanofi and Regeneron to talk to us more about COPD also known as Chronic Obstructive Pulmonary ...

Sure, having a cold or respiratory infection can temporarily make it harder to breathe. But if excessive coughing and ...

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is a prescription drug used to treat COPD. With COPD, you have lung damage that worsens over time ...

reckons a chronic obstructive pulmonary disease (COPD) drug will be included – and is preparing to contribute to the process. ICER isn't officially involved in the price negotiations introduced ...

Tudorza and Duaklir are inhaled respiratory drugs for chronic obstructive pulmonary disease (COPD) – and at the time of the deal Tudorza (aclidinium bromide), a long-acting muscarinic agonist ...

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type ...

The decision could significantly expand use of what is already one of the industry’s best-selling ... pulmonary disease, or COPD, that can’t be controlled with other medications.

However, the COPD segment is expected to see substantial growth due to advancements in treatment. By Medication Class: Key segments include combination drugs, inhaled corticosteroids (ICS), short ...

Regeneron and Sanofi shares edged higher Friday after their drug to treat chronic obstructive pulmonary disease (COPD) received approval from the Food and Drug Administration (FDA). The drug ...